Pacific GeneTech reports positive for vaccine targeting E. coli in swine
1 September 2021 Pacific GeneTech (PGT) reports positive results in a recent trial for its oral Salmonella-based cross-protective vaccine targeting E. coli in swine. The study was conducted at TRB in the US.
The trial compared PGT's vaccine to Arko Labs’ Edema Vac vaccine, against E. Coli (F-18). The study used clinical signs and bacteriology as endpoints.
Results demonstrated that the PGT vaccine was safe and protective against E. coli (F-18) in pigs and compared favorably with the Arko commercially available vaccine. The PGT vaccine was well tolerated, with no ill effects, and with a numerical trend towards performance of pigs given the PGT vaccine.
The PGT vaccine is a live attenuated recombinant vaccine based on PGT’s Aegis vaccine platform. It has also demonstrated protection against multiple serogroups of Salmonella in poultry. As a next step, PGT intends to conduct challenge trials against Salmonella Typhimurium in swine.
ABOUT PACIFIC GENETECH
Pacific GeneTech (www.pacificgenetech.com) develops and commercializes next-generation vaccines and biologics for areas of high unmet or underserved needs in food safety and animal health. PGT's proprietary "Aegis" vaccine platform combines cross-protective antigens and immunopotentiators in PGT vectors for broad spectrum protection against multiple strains and species of infectious diseases. The PGT vaccines can be administered orally or by injection in both live and inactivated forms. PGT's "Hercules" adjuvant/delivery system provides enhanced efficacy of inactivated and DNA vaccines, and its "Argo" yeast vector is a safe, flexible and robust carrier of immunogenic material.
PGT has out-licensed two of its leading poultry vaccines addressing economically important gastro-intestinal pathogens and has out-licensed its Hercules adjuvant for use in third-party vaccines. Vaccines for other pathogens and animal species are under development, including an experimental DNA vaccine for African Swine Fever. PGT is developing other applications for its Hercules adjuvant/delivery system and for the Argo vector. PGT, through its affiliate company, PGTx, has commenced programs with collaborators addressing human dysentery and related diseases, and malaria.